Commentary
The harms of benzodiazepines for patients with dementia
Paula A. Rochon, Nicholas Vozoris and Sudeep S. Gill
CMAJ April 10, 2017 189 (14) E517-E518; DOI: https://doi.org/10.1503/cmaj.170193
Paula A. Rochon
Women’s College Research Institute (Rochon), Women’s College Hospital; Department of Medicine (Rochon, Vozoris), Institute of Health Policy, Management, and Evaluation (Rochon), University of Toronto; Department of Medicine and Keenan Research Centre in the Li Ka Shing Knowledge Institute (Vozoris), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Gill), Queen’s University; Institute for Clinical Evaluative Sciences (Gill), Kingston, Ont.
MD MPHNicholas Vozoris
Women’s College Research Institute (Rochon), Women’s College Hospital; Department of Medicine (Rochon, Vozoris), Institute of Health Policy, Management, and Evaluation (Rochon), University of Toronto; Department of Medicine and Keenan Research Centre in the Li Ka Shing Knowledge Institute (Vozoris), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Gill), Queen’s University; Institute for Clinical Evaluative Sciences (Gill), Kingston, Ont.
MD MHSCSudeep S. Gill
Women’s College Research Institute (Rochon), Women’s College Hospital; Department of Medicine (Rochon, Vozoris), Institute of Health Policy, Management, and Evaluation (Rochon), University of Toronto; Department of Medicine and Keenan Research Centre in the Li Ka Shing Knowledge Institute (Vozoris), St. Michael’s Hospital, Toronto, Ont.; Department of Medicine (Gill), Queen’s University; Institute for Clinical Evaluative Sciences (Gill), Kingston, Ont.
MD MScIn this issue
Article tools
The harms of benzodiazepines for patients with dementia
Paula A. Rochon, Nicholas Vozoris, Sudeep S. Gill
CMAJ Apr 2017, 189 (14) E517-E518; DOI: 10.1503/cmaj.170193